文献速递抗菌药物管理肝肾功能剂量调整特殊人群用药

Sulopenem:治疗多重耐药细菌所致尿路感染的静脉与口服青霉烯类抗菌药

Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria.
PubMed 文献 · Drugs · 2022-03-16

Sulopenem 是一种对氟喹诺酮耐药、产超广谱β-内酰胺酶(ESBL)及多重耐药(MDR)肠杆菌目有体外活性的静脉和口服青霉烯类抗菌药,开发用于单纯性和复杂性尿路感染(UTI)及腹腔感染。本综述聚焦其用于 UTI,总结其化学结构、抗菌谱、药代动力学/药效学、临床 III 期试验(SURE-1、SURE-2)及安全性数据。

要点

  • 对产 ESBL/CTX-M/Amp-C 或 MDR 表型的大肠埃希菌及产 ESBL 肺炎克雷伯菌,sulopenem 活性与厄他培南、美罗培南几乎相同且优于亚胺培南。
  • 口服 sulopenem etzadroxil 需与食物同服或联用丙磺舒以提高生物利用度。
  • III 期 SURE-1 显示在氟喹诺酮敏感病原感染女性中 sulopenem 未达非劣于环丙沙星,但在氟喹诺酮不敏感病原感染者中表现优效。

核心结论

  • Sulopenem 静脉和/或口服是治疗单纯性和复杂性 UTI 的潜在耐受良好且有效的选择,尤其适用于对常用药物耐药(如氟喹诺酮耐药大肠埃希菌)或一线治疗失败/不耐受的患者。
  • 该药可能用于门诊口服治疗,住院患者可静脉后序贯口服,也可用于从非 sulopenem 静脉治疗序贯口服。

研究设计与样本

  • 本综述聚焦 sulopenem 用于 UTI,汇总其体外活性、药代动力学/药效学、动物模型及 III 期临床试验(SURE-1、SURE-2)数据。
  • SURE-1 为 III 期临床试验,在女性单纯性 UTI 中比较 sulopenem 与环丙沙星。
  • SURE-2 为 III 期临床试验,在复杂性 UTI 中比较静脉 sulopenem 后口服 sulopenem etzadroxil/丙磺舒与厄他培南(后序贯口服)。

主要发现

  • 体外研究中,sulopenem 对粪肠球菌、单核细胞增生李斯特菌、甲氧西林敏感金黄色葡萄球菌(MSSA)和表皮葡萄球菌的活性高于美罗培南和厄他培南,对无乳链球菌、肺炎链球菌和化脓性链球菌的活性与碳青霉烯类相似。
  • 对携带 ESBL、CTX-M 或 Amp-C 酶或呈 MDR 表型的大肠埃希菌以及产 ESBL 肺炎克雷伯菌,sulopenem 活性与厄他培南和美罗培南几乎相同且高于亚胺培南。
  • 健康受试者中,静脉 sulopenem 分布容积(Vd)为 15.8–27.6 L,总清除率(CLT)18.9–24.9 L/h,蛋白结合率约 10%,消除半衰期(t½)0.88–1.03 h,肾清除率(CLR)8.0–10.6 L/h,1000 mg 剂量后 35.5%±6.7% 以原形经尿回收。
  • 口服 sulopenem etzadroxil 空腹生物利用度为 20–34%;与食物同服使口服 sulopenem(500 mg 每日两次)AUC 增加 23.6%,与 500 mg 丙磺舒同服时增加 62%。
  • SURE-1 中,在氟喹诺酮敏感病原感染女性中 sulopenem 因治愈试验访视时无症状菌尿率更高而未达非劣于环丙沙星;但在氟喹诺酮不敏感病原感染者中 sulopenem etzadroxil/丙磺舒优于环丙沙星,在尿培养阳性所有患者中非劣效。

关键数值与推荐

  • IV sulopenem 在健康受试者中 Vd 15.8–27.6 L,CLT 18.9–24.9 L/h,蛋白结合率约 10%,t½ 0.88–1.03 h,CLR 8.0–10.6 L/h,1000 mg 剂量后 35.5%±6.7% 原形尿回收。
  • 口服 sulopenem etzadroxil 空腹生物利用度 20–34%;食物使口服 sulopenem(500 mg 每日两次)AUC 增加 23.6%(单用)和 62%(联用 500 mg 丙磺舒)。
  • 动物模型中,抑菌与 %f T > MIC 8.6–17% 相关,2-log10 杀菌与 12–28% 相关;尚无耐药抑制的药效学靶标。
  • 空腹受试者尿中 sulopenem 浓度范围 21.8–420.0 mg/L(中位数 84.4 mg/L),进食受试者 28.8–609.0 mg/L(中位数 87.3 mg/L)。
  • 报告的治疗中出现不良事件(TEAEs)发生率≥1% 者(从高到低)为腹泻、恶心、头痛、呕吐和头晕;停药率低且与对照药无差异。

临床怎么用

  • Sulopenem 可用于单纯性和复杂性 UTI,尤其适用于对常用药物耐药(如氟喹诺酮耐药大肠埃希菌)或一线治疗失败/不耐受的患者。
  • 口服 sulopenem etzadroxil 应与食物同服或联用丙磺舒以提高生物利用度。
  • 住院患者可静脉使用 sulopenem 后序贯口服,也可从非 sulopenem 静脉治疗序贯口服。
  • 抗菌药物管理项目需制定该口服和静脉青霉烯类的使用指南。

局限性

  • 需要更多临床数据全面评估 sulopenem 的临床疗效和安全性,尤其是由耐药病原(如产 ESBL、Amp-C、MDR 大肠埃希菌)引起的复杂性 UTI 患者。
  • SURE-1 和 SURE-2 中 sulopenem 因无症状菌尿率更高而未达非劣效。
  • 目前尚不清楚 Iterum 是否计划申请 EMA 或日本监管批准。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Sulopenem (formerly known as CP-70,429, and CP-65,207 when a component of a racemic mixture with its R isomer) is an intravenous and oral penem that possesses in vitro activity against fluoroquinolone-resistant, extended spectrum β-lactamases (ESBL)-producing, multidrug-resistant (MDR) Enterobacterales. Sulopenem is being developed to treat patients with uncomplicated and complicated urinary tract infections (UTIs) as well as intra-abdominal infections. This review will focus mainly on its use in UTIs. The chemical structure of sulopenem shares properties of penicillins, cephalosporins, and carbapenems. Sulopenem is available as an oral prodrug formulation, sulopenem etzadroxil, which is hydrolyzed by intestinal esterases, resulting in active sulopenem. In early studies, the S isomer of CP-65,207, later developed as sulopenem, demonstrated greater absorption, higher drug concentrations in the urine, and increased stability against the renal enzyme dehydropeptidase-1 compared with the R isomer, which set the stage for its further development as a UTI antimicrobial. Sulopenem is active against both Gram-negative and Gram-positive microorganisms. Sulopenem's β-lactam ring alkylates the serine residues of penicillin-binding protein (PBP), which inhibits peptidoglycan cross-linking. Due to its ionization and low molecular weight, sulopenem passes through outer membrane proteins to reach PBPs of Gram-negative bacteria. While sulopenem activity is unaffected by many β-lactamases, resistance arises from alterations in PBPs (e.g., methicillin-resistant Staphylococcus aureus [MRSA]), expression of carbapenemases (e.g., carbapenemase-producing Enterobacterales and in Stenotrophomonas maltophilia), reduction in the expression of outer membrane proteins (e.g., some Klebsiella spp.), and the presence of efflux pumps (e.g., MexAB-OprM in Pseudomonas aeruginosa), or a combination of these mechanisms. In vitro studies have reported that sulopenem demonstrates greater activity than meropenem and ertapenem against Enterococcus faecalis, Listeria monocytogenes, methicillin-susceptible S. aureus (MSSA), and Staphylococcus epidermidis, as well as similar activity to carbapenems against Streptococcus agalactiae, Streptococcus pneumoniae, and Streptococcus pyogenes. With some exceptions, sulopenem activity against Gram-negative aerobes was less than ertapenem and meropenem but greater than imipenem. Sulopenem activity against Escherichia coli carrying ESBL, CTX-M, or Amp-C enzymes, or demonstrating MDR phenotypes, as well as against ESBL-producing Klebsiella pneumoniae, was nearly identical to ertapenem and meropenem and greater than imipenem. Sulopenem exhibited identical or slightly greater activity than imipenem against many Gram-positive and Gram-negative anaerobes, including Bacteroides fragilis. The pharmacokinetics of intravenous sulopenem appear similar to carbapenems such as imipenem-cilastatin, meropenem, and doripenem. In healthy subjects, reported volumes of distribution (Vd) ranged from 15.8 to 27.6 L, total drug clearances (CLT) of 18.9-24.9 L/h, protein binding of approximately 10%, and elimination half-lives (t½) of 0.88-1.03 h. The estimated renal clearance (CLR) of sulopenem is 8.0-10.6 L/h, with 35.5% ± 6.7% of a 1000 mg dose recovered unchanged in the urine. An ester prodrug, sulopenem etzadroxil, has been developed for oral administration. Initial investigations reported a variable oral bioavailability of 20-34% under fasted conditions, however subsequent work showed that bioavailability is significantly improved by administering sulopenem with food to increase its oral absorption or with probenecid to reduce its renal tubular secretion. Food consumption increases the area under the curve (AUC) of oral sulopenem (500 mg twice daily) by 23.6% when administered alone and 62% when administered with 500 mg of probenecid. Like carbapenems, sulopenem demonstrates bactericidal activity that is associated with the percentage of time that free concentrations exceed the MIC (%f T > MIC). In animal models, bacteriostasis was associated with %f T > MICs ranging from 8.6 to 17%, whereas 2-log10 kill was seen at values ranging from 12 to 28%. No pharmacodynamic targets have been documented for suppression of resistance. Sulopenem concentrations in urine are variable, ranging from 21.8 to 420.0 mg/L (median 84.4 mg/L) in fasted subjects and 28.8 to 609.0 mg/L (median 87.3 mg/L) in those who were fed. Sulopenem has been compared with carbapenems and cephalosporins in guinea pig and murine systemic and lung infection animal models. Studied pathogens included Acinetobacter calcoaceticus, B. fragilis, Citrobacter freundii, Enterobacter cloacae, E. coli, K. pneumoniae, Proteus vulgaris, and Serratia marcescens. These studies reported that overall, sulopenem was non-inferior to carbapenems but appeared to be superior to cephalosporins. A phase III clinical trial (SURE-1) reported that sulopenem was not non-inferior to ciprofloxacin in women infected with fluoroquinolone-susceptible pathogens, due to a higher rate of asymptomatic bacteriuria in sulopenem-treated patients at the test-of-cure visit. However, the researchers reported superiority of sulopenem etzadroxil/probenecid over ciprofloxacin for the treatment of uncomplicated UTIs in women infected with fluoroquinolone/non-susceptible pathogens, and non-inferiority in all patients with a positive urine culture. A phase III clinical trial (SURE-2) compared intravenous sulopenem followed by oral sulopenem etzadroxil/probenecid with ertapenem in the treatment of complicated UTIs. No difference in overall success was noted at the end of therapy. However, intravenous sulopenem followed by oral sulopenem etzadroxil was not non-inferior to ertapenem followed by oral stepdown therapy in overall success at test-of-cure due to a higher rate of asymptomatic bacteriuria in the sulopenem arm. After a meeting with the US FDA, Iterum stated that they are currently evaluating the optimal design for an additional phase III uncomplicated UTI study to be conducted prior to the potential resubmission of the New Drug Application (NDA). It is unclear at this time whether Iterum intends to apply for EMA or Japanese regulatory approval. The safety and tolerability of sulopenem has been reported in various phase I pharmacokinetic studies and phase III clinical trials. Sulopenem (intravenous and oral) appears to be well tolerated in healthy subjects, with and without the coadministration of probenecid, with few serious drug-related treatment-emergent adverse events (TEAEs) reported to date. Reported TEAEs affecting ≥1% of patients were (from most to least common) diarrhea, nausea, headache, vomiting and dizziness. Discontinuation rates were low and were not different than comparator agents. Sulopenem administered orally and/or intravenously represents a potentially well tolerated and effective option for treating uncomplicated and complicated UTIs, especially in patients with documented or highly suspected antimicrobial pathogens to commonly used agents (e.g. fluoroquinolone-resistant E. coli), and in patients with documented microbiological or clinical failure or patients who demonstrate intolerance/adverse effects to first-line agents. This agent will likely be used orally in the outpatient setting, and intravenously followed by oral stepdown in the hospital setting. Sulopenem also allows for oral stepdown therapy in the hospital setting from intravenous non-sulopenem therapy. More clinical data are required to fully assess the clinical efficacy and safety of sulopenem, especially in patients with complicated UTIs caused by resistant pathogens such as ESBL-producing, Amp-C, MDR E. coli. Antimicrobial stewardship programs will need to create guidelines for when this oral and intravenous penem should be used.

来源:Drugs,查看原文。版权归原作者所有。

引用

  1. Zhanel GG, Pozdirca M, Golden AR, et al. Sulopenem: An Intravenous and Oral Penem for the Treatment of Urinary Tract Infections Due to Multidrug-Resistant Bacteria. Drugs. 2022. PMID: 35294769. doi:10.1007/s40265-022-01688-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。